In the patient group, which included those who were less likely to benefit from either SGLT2i or GLP-1 RA, the commonly observed PMHs were dyslipidemia and hypertension (56.9% and 37.3%), respectively. This evidence concerns the gene GLP1R and metabolic syndrome.